ARS Pharmaceuticals, Inc.
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.
On July 7, 2026, the Board of Directors (the “Board”) of ARS Pharmaceuticals, Inc. (the “Company”) appointed the Company’s current President Donn Casale as the Company’s Chief Executive Officer, effective immediately, replacing Richard Lowenthal in such capacity.
Mr. Casale was also concurrently appointed to the Board as a Class III director, to serve until the Company’s 2029 annual meeting of stockholders.
Mr. Lowenthal was notified on July 6, 2026 that his employment was being terminated without cause, effective immediately.
Extracted from this filing and checked against the source text.
Donn Casale was appointed as Chief Executive Officer at ARS Pharmaceuticals, Inc..
On July 7, 2026, the Board of Directors (the “Board”) of ARS Pharmaceuticals, Inc. (the “Company”) appointed the Company’s current President Donn Casale as the Company’s Chief Executive Officer, effective immediately, replacing Richard Lowenthal in such capacity.View on SEC.gov
Donn Casale was appointed as Class III director at ARS Pharmaceuticals, Inc..
Mr. Casale was also concurrently appointed to the Board as a Class III director, to serve until the Company’s 2029 annual meeting of stockholders.View on SEC.gov
Richard Lowenthal departed as Chief Executive Officer at ARS Pharmaceuticals, Inc..
Mr. Lowenthal was notified on July 6, 2026 that his employment was being terminated without cause, effective immediately.View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.